Page 1,964«..1020..1,9631,9641,9651,966..1,9701,980..»

Progeny 'mega cells' pivotal in adult stem cell transplant

Posted: October 22, 2014 at 12:47 pm

A new research has identified that 'megakaryocytes' or 'megacells' are responsible for playing a critical role in adult stem cell transplant.

Hematopoietic stem cells differentiate to generate megakaryocytes in bone marrow and the study has shown that the hematopoietic stem cells (the parent cells) could be directly controlled by their own progeny (megakaryocytes).

The results had suggested that megakaryocytes might be used clinically to facilitate adult stem cell regeneration and to expand cultured cells for adult stem cell transplants.

Researchers at Stowers Institute for Medical Research had discovered that megakaryocytes had directly regulated the function of murine hematopoietic stem cellsadult stem cells that had formed the blood and immune cells and that had constantly renewed the body's blood supply. These cells could also develop into all types of blood cells, including white blood cells, red blood cells, and platelets.

Because of their remarkable ability to renew themselves and differentiate into other cells, hematopoietic stems cells have been used to treat many diseases and conditions. The transplantation of isolated human hematopoietic stem cells has been used in the treatment of anemia, immune deficiencies and other diseases, including cancer.

The study was published in the journal Nature Medicine.

(Posted on 20-10-2014)

Post your comments

Information on States of India:

Read more from the original source:
Progeny 'mega cells' pivotal in adult stem cell transplant

Posted in Stem Cells | Comments Off on Progeny 'mega cells' pivotal in adult stem cell transplant

Stem cell and clinical research advances to be presented at NYSCF's Ninth Annual Conference

Posted: October 22, 2014 at 12:41 pm

PUBLIC RELEASE DATE:

20-Oct-2014

Contact: David McKeon 212-365-7440 New York Stem Cell Foundation @nyscf

Leaders in translational stem cell research from around the world will present the latest advances in stem cell science that are leading to better treatments and cures to disease and injury at The New York Stem Cell Foundation's Ninth Annual Translational Stem Cell Research Conference.

The opening day of the conference includes a panel discussion on large scale, big data stem cell and genetic initiatives moderated by Susan L. Solomon, JD, CEO and Co-founder of The New York Stem Cell Foundation (NYSCF), with panelists George Church, PhD, Harvard Medical School; John Greally, PhD, Albert Einstein College of Medicine; Scott Noggle, PhD, The NYSCF Research Institute; and Eric Schadt, PhD, the Icahn School of Medicine at Mount Sinai.

Later that day, a discussion on neurodegeneration includes Kevin Eggan, PhD, Harvard University and the NYSCF Research Institute, who will discuss his research identifying an existing drug candidate that may be of use treating ALS and is entering clinical trials in the coming year. The following session on cell reprogramming and cancer includes Michael Milone, MD, PhD, University of Pennsylvania, who will discuss recent research results from his lab and his colleagues including the results of a clinical trial for leukemia featured in The New York Times last week. The first day closes with a conversation on personalized medicine featuring Dieter Egli, PhD, NYSCF Robertson Investigator at the NYSCF Research Institute and Columbia University; Rudolf Jaenisch, MD, The Whitehead Institute; and Sir Ian Wilmut, FRS, FRSE, University of Edinburgh.

On October 23, the day will begin with remarks by Kenneth Adams and Kyle Kimball, President of the Empire State Development Corporation and President of the New York City Economic Development Corporation, respectively. The session on translating innovation from the laboratory to the clinic features Stephen Chang, PhD, of the NYSCF Research Institute and Richard Pearse, PhD, of the Harvard Catalyst and eagle-i Network who will discuss their collaboration on the first publicly available induced pluripotent stem cell database. The day will close with a presentation on induced neuronal cells and cell transdifferentiation from the 2014 NYSCF Robertson Stem Cell Prize recipient, Marius Wernig, MD, PhD, of Stanford University School of Medicine.

Sir Ian Wilmut will give the keynote address on October 22nd and Dr. Rudolf Jaenisch will give the keynote address on the last day of the conference.

The full conference agenda can be found at http://www.nyscf.org/conference

###

Read the original here:
Stem cell and clinical research advances to be presented at NYSCF's Ninth Annual Conference

Posted in Cell Medicine | Comments Off on Stem cell and clinical research advances to be presented at NYSCF's Ninth Annual Conference

Human Skin Cells Reprogrammed Directly Into Brain Cells

Posted: October 22, 2014 at 12:41 pm

Contact Information

Available for logged-in reporters only

Newswise Scientists have described a way to convert human skin cells directly into a specific type of brain cell affected by Huntingtons disease, an ultimately fatal neurodegenerative disorder. Unlike other techniques that turn one cell type into another, this new process does not pass through a stem cell phase, avoiding the production of multiple cell types, the studys authors report.

The researchers, at Washington University School of Medicine in St. Louis, demonstrated that these converted cells survived at least six months after injection into the brains of mice and behaved similarly to native cells in the brain.

Not only did these transplanted cells survive in the mouse brain, they showed functional properties similar to those of native cells, said senior author Andrew S. Yoo, PhD, assistant professor of developmental biology. These cells are known to extend projections into certain brain regions. And we found the human transplanted cells also connected to these distant targets in the mouse brain. Thats a landmark point about this paper.

The work appears Oct. 22 in the journal Neuron.

The investigators produced a specific type of brain cell called medium spiny neurons, which are important for controlling movement. They are the primary cells affected in Huntingtons disease, an inherited genetic disorder that causes involuntary muscle movements and cognitive decline usually beginning in middle-adulthood. Patients with the condition live about 20 years following the onset of symptoms, which steadily worsen over time.

The research involved adult human skin cells, rather than more commonly studied mouse cells or even human cells at an earlier stage of development. In regard to potential future therapies, the ability to convert adult human cells presents the possibility of using a patients own skin cells, which are easily accessible and wont be rejected by the immune system.

To reprogram these cells, Yoo and his colleagues put the skin cells in an environment that closely mimics the environment of brain cells. They knew from past work that exposure to two small molecules of RNA, a close chemical cousin of DNA, could turn skin cells into a mix of different types of neurons.

In a skin cell, the DNA instructions for how to be a brain cell, or any other type of cell, is neatly packed away, unused. In past research published in Nature, Yoo and his colleagues showed that exposure to two microRNAs called miR-9 and miR-124 altered the machinery that governs packaging of DNA. Though the investigators still are unraveling the details of this complex process, these microRNAs appear to be opening up the tightly packaged sections of DNA important for brain cells, allowing expression of genes governing development and function of neurons.

Link:
Human Skin Cells Reprogrammed Directly Into Brain Cells

Posted in Cell Medicine | Comments Off on Human Skin Cells Reprogrammed Directly Into Brain Cells

Understanding What Happens In Stem Cell Treatment Centers …

Posted: October 22, 2014 at 12:40 pm

Stem cell therapy has been a field of much concern to many scientists and scientific facilities for a very long time. This therapy uses stem cells to treat and prevent conditions and diseases in both humans and animals. This medication is still under intensive research and most of the treatments discovered are still not in any use. Most stem cell treatment centers practice bone marrow transplant.

Bone marrow transplant is more advanced making it to be used more than other treatments. It treats blood disorders such as lymphoma and leukemia cancer patients. Higher levels of efficiency and accuracy are still achievable through more research. In future, treatments for deafness, missing teeth, heart diseases, diabetes, HIV/AIDS, neurodegeneration, blood cell formation, infertility, baldness, and other conditions will be found.

Cells are derived from many different sources and some are under serious criticism. Embryonic stem cells form the bulk of all the cells used because they are easier to derive. They get isolated from embryos first before being taken through culturing and preparation procedures to ready them for use. Human cloning and abortion politics are highly stirred by these methods. Other methods include pluripotent stem cells induction and utilization of methods of somatic cell nuclear transfer.

Treatments that base on transplanting of stored umbilical cord blood have faced a lot of challenges in marketing because of the wide criticism in this area. Many research facilities therefore face financial difficulties and shut down while researchers get discouraged by these difficulties and controversies. Some of the treatments are not complete yet because of these challenges.

Diseases destroy and kill cells reducing their numbers, stem cell therapy works to restore the lost or damaged cells in the area that is affected. When introduced into live tissues, they result in formation of new cells. This way, Parkinson disease, amyyotrophic lateral sclerosis, Alzheimer disease, and other brain degenerating diseases are curable and preventable. Similarly, wounds can be treated by formation of normal body tissues instead of typical scar tissues.

Many people have a lot of hopes in these treatments hence it is good to understand what they can do and what they cannot. First, it is worth knowing that the body has different types of stem cells and each type is specific to the function it does in human bodies. That is the reason why unrelated medical conditions cannot be treated by the same kind of cells. Tissue specific cells are specific in what they can do hence they cannot be used for functions they are not specialized for.

Various therapies use very complicated techniques to introduce the cells into the body. The introduction process is itself very risky and involves a lot of risks to the patient. After the cells are derived from the body, they are cultured in before they are reintroduced into the body. The culturing targets to instruct the cells to behave in a given way once introduced into the body. Such instructions may fail causing severe effects.

It is very expensive to go for the therapy too. Lack of finances therefore limit the number of people that can afford the treatment. This makes the majority to seek other treatment options.

If you would like to know more about stem cell treatment centers you can visit our website today. To get further details about our research facilities, take a look at our homepage on http://www.indianastemcelltreatmentcenter.com now.

Visit link:
Understanding What Happens In Stem Cell Treatment Centers ...

Posted in Cell Therapy | Comments Off on Understanding What Happens In Stem Cell Treatment Centers …

StemGenex New Clinical Study Aims to Provide Relief to …

Posted: October 22, 2014 at 12:40 pm

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

SOURCE:

StemGenex partners with Stem Cell Research Centre Registering a new Clinical Study for Osteoarthritis through Clinicaltrials.gov

La Jolla, CA (PRWEB) October 21, 2014

StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced their newest clinical study in partnership with Stem Cell Research Centre for Osteoarthritis. StemGenex and Stem Cell Research Centre (SCRC) believe that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with life threatening diseases.

There are currently 21 million people in the U.S. alone, who suffer from Osteoarthritis. The most common symptoms are joint pain and stiffness which most commonly affect the neck, lower back, knees, shoulders and hips. These symptoms gradually worsen over time ultimately leading to the need for a total joint replacement procedure. StemGenex believe their new clinical study may provide patients improved mobility, significantly reduced pain and ultimately a better quality of life without needing joint replacement surgery.

This clinical study makes stem cell therapy for osteoarthritis accessible to the millions of individuals currently struggling with this painful disease. The protocol used in these stem cell treatments is unique to StemGenex and SCRC, having the possibility of being more effective than other stem cell treatments currently available. These treatments will utilize a multiple administration method which also includes injections precisely targeting the joint space. StemGenex believes these treatments may be able to keep patients from needing joint replacement surgery in the future, due to regeneration of cartilage in the joint.

This clinical study will be conducted under the leadership of the principal investigator,Dr. Jeremiah McDole, Ph.D. Dr. McDole states, We are excited to begin enrolling for this new study. We have high expectations for what we will learn and what advancements can ultimately be implemented. Of course, our focus is always set toward the near future and what can be done to help improve the lives of those individuals with Osteoarthritis.

This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval of Stem Cell Research Centre (SCRC). There are many patients who are exploring stem cell therapy for osteoarthritis and it is important they have access to top-tier stem cell therapy. By providing patients access to stem cell studies registered through The National Institutes of Health, patients now have the ability to choose treatment that focuses on both safety and efficacy.

Rita Alexander, founder and president of StemGenex stated With so many people suffering from Osteoarthritis its absolutely wonderful to provide a treatment that has not only shown efficacy but also to be minimally invasive. Over the last several years we have observed significant improvement in the symptoms of Osteoarthritis patients through stem cell treatment. Through these registered clinical studies, we will now be able to publish our findings over the next few years.

Originally posted here:
StemGenex New Clinical Study Aims to Provide Relief to ...

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on StemGenex New Clinical Study Aims to Provide Relief to …

Spice Compound Boosts Brain Stem Cells | Worldhealth.net …

Posted: October 22, 2014 at 12:40 pm

Aromatic (ar-) turmerone, a bioactive compound found in the curry spice turmeric, has been shown to promote stem cell proliferation and differentiation in the brain. Adele Rueger and colleagues from the Institute of Neuroscience and Medicine in Jlich, Germany, investigated the effects of ar-turmerone on neural stem cell proliferation (NSC) and differentiation both in vitro and in vivo. In vitro, ar-turmerone was shown to increase NSC proliferation by up to 80%. Furthermore, cell differentiation was also seen to accelerate in ar-turmerone-treated cells compared to untreated control cells. To test ar-turmerone in vivo, the researchers injected adult rats with ar-turmerone. Imaging showed that the subventricular zone (SVZ) was wider, and the hippocampus expanded, in the brains of rats injected with ar-turmerone than in control animals. The researchers say that the findings suggest that ar-turmerone could be a future drug candidate for treating neurological illnesses, such as stroke and Alzheimer's disease.

Graf R, Fink GR, Schroeter M, Rueger MA. Aromatic-turmerone induces neural stem cell proliferation in vitro and in vivo. Stem Cell Research & Therapy. 2014;5:100.

Regularly engaging in moderate-to-vigorous exercise appears to help protect the brain by maintaining the structural integrity of white matter.

A compound found in the popular curry spice turmeric has been shown to promote stem cell proliferation and differentiation in the brain.

Eating plenty of fruit and vegetables may protect both mental and physical wellbeing.

An extract of a wild berry native to North America boosts the effectiveness of the chemotherapy drug gemcitabine.

Making healthy lifestyle choices could prevent as many as 4 out of 5 coronary events in men.

Women who go up a skirt size after the age of 25 are at increased risk of postmenopausal breast cancer.

Older men and women who volunteer for 2-3 hours a week enjoy physical, mental, and emotional benefits.

Each day of hospitalization due to an infection raises by 1% the risk that the infection will be multidrug-resistant.

See the article here:
Spice Compound Boosts Brain Stem Cells | Worldhealth.net ...

Posted in Cell Therapy | Comments Off on Spice Compound Boosts Brain Stem Cells | Worldhealth.net …

StemGenex New Clinical Study Aims to Provide Relief to Osteoarthritis Patients through Latest Stem Cell Therapy

Posted: October 22, 2014 at 12:40 pm

La Jolla, CA (PRWEB) October 21, 2014

StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced their newest clinical study in partnership with Stem Cell Research Centre for Osteoarthritis. StemGenex and Stem Cell Research Centre (SCRC) believe that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with life threatening diseases.

There are currently 21 million people in the U.S. alone, who suffer from Osteoarthritis. The most common symptoms are joint pain and stiffness which most commonly affect the neck, lower back, knees, shoulders and hips. These symptoms gradually worsen over time ultimately leading to the need for a total joint replacement procedure. StemGenex believe their new clinical study may provide patients improved mobility, significantly reduced pain and ultimately a better quality of life without needing joint replacement surgery.

This clinical study makes stem cell therapy for osteoarthritis accessible to the millions of individuals currently struggling with this painful disease. The protocol used in these stem cell treatments is unique to StemGenex and SCRC, having the possibility of being more effective than other stem cell treatments currently available. These treatments will utilize a multiple administration method which also includes injections precisely targeting the joint space. StemGenex believes these treatments may be able to keep patients from needing joint replacement surgery in the future, due to regeneration of cartilage in the joint.

This clinical study will be conducted under the leadership of the principal investigator,Dr. Jeremiah McDole, Ph.D. Dr. McDole states, We are excited to begin enrolling for this new study. We have high expectations for what we will learn and what advancements can ultimately be implemented. Of course, our focus is always set toward the near future and what can be done to help improve the lives of those individuals with Osteoarthritis.

This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval of Stem Cell Research Centre (SCRC). There are many patients who are exploring stem cell therapy for osteoarthritis and it is important they have access to top-tier stem cell therapy. By providing patients access to stem cell studies registered through The National Institutes of Health, patients now have the ability to choose treatment that focuses on both safety and efficacy.

Rita Alexander, founder and president of StemGenex stated With so many people suffering from Osteoarthritis its absolutely wonderful to provide a treatment that has not only shown efficacy but also to be minimally invasive. Over the last several years we have observed significant improvement in the symptoms of Osteoarthritis patients through stem cell treatment. Through these registered clinical studies, we will now be able to publish our findings over the next few years.

This clinical study follows on the heels of StemGenex latest clinical studies for both Parkinsons disease and Multiple Sclerosis. Stem cell treatment studies are currently being offered by StemGenex partnering with Stem Cell Research Centre (SCRC) to patients diagnosed with Osteoarthritis as well as degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative conditions including Multiple Sclerosis, Alzheimers disease, stroke recovery and others.

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact@stemgenex.com

More here:
StemGenex New Clinical Study Aims to Provide Relief to Osteoarthritis Patients through Latest Stem Cell Therapy

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on StemGenex New Clinical Study Aims to Provide Relief to Osteoarthritis Patients through Latest Stem Cell Therapy

Stem cell treatment of spinal cord injuries [Pharyngula]

Posted: October 22, 2014 at 12:40 pm

I have to admit that my first response to these reports out of Britain that stem cells had been successfully used to repair a complete spinal cord transection was skepticism incredulity even. Theyre reporting that a man with a completely severed spinal cord at level T10-T11 is able to walk again! The Guardian gushes! The Daily Mail gets in the act (always a bad sign)! When I read that the patient had an 8mm gap in his spinal cord that had been filling up with scar tissue for the last two years, I was even more doubtful: under the best of conditions, it was unlikely that youd get substantial connectivity across that distance.

So I read the paper. Im less skeptical now, for a couple of reasons. They actually did this experiment on 3 people, and all showed degrees of improvement, although the newspapers are all focusing on just the one who had the greatest change. The gradual changes are all documented thoroughly and believably. And, sad to say, the improvements in the mans motor and sensory ability are more limited and more realistic than most of the accounts would have you think.

The story is actually in accord with what weve seen in stem cell repair of spinal cord injury in rats and mice.

Overall, they found that stem cell treatment results in an average improvement of about 25% over the post-injury performance in both sensory and motor outcomes, though the results can vary widely between animals. For sensory outcomes the degree of improvement tended to increase with the number of cells introduced scientists are often reassured by this sort of dose response, as it suggests a real underlying biologically plausible effect. So the good news is that stem cell therapy does indeed seem to confer a statistically significant improvement over the residual ability of the animals both to move and feel things beyond the spinal injury site.

Significant but far from complete improvement is exactly what wed expect, and that improvement is a very, very good thing. It is an accomplishment to translate animal studies into getting measurable clinical improvements in people.

The basic procedure is straightforward. There is a population of neural cells in humans that do actively and continuously regenerate: the cells of the olfactory bulb. So what they did is remove one of the patients own olfactory bulbs, dissociate it into a soup of isolated cells, and inject them into locations above and below the injury. They also bridged the gap with strips of nerve tissue harvested from the patients leg. The idea is that the proliferating cells and the nerves would provide a nerve growth-friendly environment and build substrate bridges that would stimulate the damaged cells and provide a path for regrowth.

Big bonus: this was an autologous transplant (from the patients own tissues), so there was no worry about immune system rejection. There were legitimate worries about inflammation, doing further damage to the spinal cord, and provoking greater degeneration, and part of the purpose of this work was to assess the safety of the procedure. There were no complications.

Also, Im sure you were worried about this, but the lost olfactory cells also regenerated and the patients completely recovered their sense of smell.

Now heres the clinical assessment. Three patients were operated on; T1 is the one who has made all the news with the most remarkable improvement. There were also three control patients who showed no improvement over the same period.

Neurological function improved in all three transplant recipients (T1, T2, T3) during the first year postsurgery. This included a decrease of muscle spasticity (T1, T2) as well as improvement of sensory (T1, T2, T3) and motor function (T1, T2, T3) below the level of spinal cord injury.

View original post here:
Stem cell treatment of spinal cord injuries [Pharyngula]

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Stem cell treatment of spinal cord injuries [Pharyngula]

UCSD Stem Cell program begins human testing

Posted: October 21, 2014 at 10:49 pm

SAN DIEGO (CNS) - UC San Diego Health System announced Monday that human testing of injected neural stem cell therapies are underway at its Sanford Stem Cell Clinical Center.

Researchers are conducting three different trials -- one on a 26-year-old woman paralyzed after a traffic crash, and others on diabetes and leukemia patients.

"What we are seeing after years of work is the rubber hitting the road," said Lawrence Goldstein, director of the UC San Diego Stem Cell program and Sanford Stem Cell Clinical Center.

"These are three very ambitious and innovative trials," he said. "Each followed a different development path -- each addresses a very different disease or condition. It speaks to the maturation of stem cell science that we've gotten to the point of testing these very real medical applications in people."

The first tests are being made with low doses in order to ensure the safety of the patients, Goldstein said.

Working with Maryland-based Neuralstem Inc., neural stem cells were injected into the site of the paralyzed woman's spinal cord injury on Sept. 30, and she is recovering at home without complications or adverse effects, said Dr. Joseph Ciacci, a neurosurgeon at UC San Diego Health System. Her name was not released.

The researchers hope that the transplanted cells will develop into neurons that bridge the gap created by the injury, replace severed or lost nerve connections and restore at least some motor and sensory function. According to UCSD, testing in laboratory rats with spinal cord injuries were promising.

A two-year trial on about 40 Type 1 diabetes patients will involve implanting cells under the skin that were derived from embryonic stem cells, with the hope they will safely mature into pancreatic beta and other cells able to produce a continuous supply of needed insulin and other substances, according to the researchers. The first procedure is expected to take place sometime this month, according to UCSD.

Type 1 diabetes, which usually onsets during childhood and has no cure, causes the pancreas to produce little or no insulin. Patients have to inject insulin daily and rigorously manage their diet and lifestyle.

The third trial will involve a potential drug to fight chronic lymphocytic leukemia, the most common form of blood cancer in adults. Patients in the test will receive the drug via an intravenous infusion every 14 days at the UCSD Moores Cancer Center.

See the rest here:
UCSD Stem Cell program begins human testing

Posted in Maryland Stem Cells | Comments Off on UCSD Stem Cell program begins human testing

IOWA AND STEM CELLS: Braley/Ernst Race has National Impact

Posted: October 21, 2014 at 10:48 pm

IOWA AND STEM CELLS: Braley/Ernst Race has National Impact

By Don C. Reed

Iowa Congressman Bruce Braley strongly supports embryonic stem (ES) cell research.

For me, this isnt a Republican or Democratic issueits a personal one. My own nephew suffers from juvenile diabetes, and I stand with former First Lady Nancy Reagan in support of the research that might one day save his life.

http://braley.house.gov/...

His Republican rival, Joni Ernst, takes the opposite position. Ms. Ernst has sponsored personhood legislation which would give legal rights to fertilized eggs. This would almost certainly criminalize ES research, as well as threatening the existence of In Vitro Fertilization (IVF) procedures, along with other perhaps unintended consequences.

http://www.huffingtonpost.com/...

Her partys platform is crystal clear: calling for a ban on all embryonic stem cell research, both public and private.

http://thinkprogress.org/...

Does this matter, in an Iowa Senatorial race?

Excerpt from:
IOWA AND STEM CELLS: Braley/Ernst Race has National Impact

Posted in Iowa Stem Cells | Comments Off on IOWA AND STEM CELLS: Braley/Ernst Race has National Impact

Page 1,964«..1020..1,9631,9641,9651,966..1,9701,980..»